Structural Insights into Immune Recognition of the Severe Acute Respiratory Syndrome Coronavirus S Protein Receptor Binding Domain

Journal of Molecular Biology

Volumn 388, Issue 4, 2009, Pages 815-823

  Pak, John E ^a   Sharon, Chetna ^a   Satkunarajah, Malathy ^a   Auperin, Thierry C ^a   Cameron, Cheryl M ^b,c   Kelvin, David J ^b,c   Seetharaman, Jayaraman ^d   Cochrane, Alan ^a   Plummer, Francis A ^e   Berry, Jody D ^e   Rini, James M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d BROOKHAVEN NATIONAL LABORATORY   (United States)

^e PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

angiotensin converting enzyme 2; immune recognition; SARS; SARS CoV; spike glycoprotein

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY F26G19; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; SPIKE PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIGEN RECOGNITION; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN STRUCTURE; RECEPTOR BINDING; SARS CORONAVIRUS; VIRUS CELL INTERACTION;

SARS CORONAVIRUS;

EID: 67349103859     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2009.03.042     Document Type: Article

References (51)

1. Drosten C., Gunther S., Preiser W., van der Werf S., Brodt H.R., Becker S., et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348 (2003) 1967-1976
2. Ksiazek T.G., Erdman D., Goldsmith C.S., Zaki S.R., Peret T., Emery S., et al. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348 (2003) 1953-1966
3. Peiris J.S., Lai S.T., Poon L.L., Guan Y., Yam L.Y., Lim W., et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361 (2003) 1319-1325
4. Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R., Icenogle J.P., et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300 (2003) 1394-1399
5. Li W., Wong S.K., Li F., Kuhn J.H., Huang I.C., Choe H., and Farzan M. Animal origins of the severe acute respiratory syndrome coronavirus: insight from ACE2-S-protein interactions. J. Virol. 80 (2006) 4211-4219
6. Gallagher T.M., and Buchmeier M.J. Coronavirus spike proteins in viral entry and pathogenesis. Virology 279 (2001) 371-374
7. Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A., et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426 (2003) 450-454
8. Xiao X., Chakraborti S., Dimitrov A.S., Gramatikoff K., and Dimitrov D.S. The SARS-CoV S glycoprotein: expression and functional characterization. Biochem. Biophys. Res. Commun. 312 (2003) 1159-1164
9. Wong S.K., Li W., Moore M.J., Choe H., and Farzan M. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J. Biol. Chem. 279 (2004) 3197-3201
10. Li F., Li W., Farzan M., and Harrison S.C. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309 (2005) 1864-1868
11. Saif L.J. Coronavirus immunogens. Vet. Microbiol. 37 (1993) 285-297
12. Cavanagh D. The coronavirus surface glycoprotein. In: Siddell S. (Ed). The Coronaviridae (1995), Plenum Press, New York 73-114
13. Berry J.D., Jones S., Drebot M.A., Andonov A., Sabara M., Yuan X.Y., et al. Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus. J. Virol. Methods 120 (2004) 87-96
14. He Y., Zhou Y., Liu S., Kou Z., Li W., Farzan M., and Jiang S. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem. Biophys. Res. Commun. 324 (2004) 773-781
15. Bisht H., Roberts A., Vogel L., Bukreyev A., Collins P.L., Murphy B.R., et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc. Natl Acad. Sci. USA 101 (2004) 6641-6646
16. Yang Z.Y., Kong W.P., Huang Y., Roberts A., Murphy B.R., Subbarao K., and Nabel G.J. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428 (2004) 561-564
17. See R.H., Zakhartchouk A.N., Petric M., Lawrence D.J., Mok C.P., Hogan R.J., et al. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. J. Gen. Virol. 87 (2006) 641-650
18. Bukreyev A., Lamirande E.W., Buchholz U.J., Vogel L.N., Elkins W.R., St Claire M., et al. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 363 (2004) 2122-2127
19. Zakhartchouk A.N., Sharon C., Satkunarajah M., Auperin T., Viswanathan S., Mutwiri G., et al. Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine. Vaccine 25 (2007) 136-143
20. Du L., Zhao G., He Y., Guo Y., Zheng B.J., Jiang S., and Zhou Y. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine 25 (2007) 2832-2838
21. He Y., Lu H., Siddiqui P., Zhou Y., and Jiang S. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J. Immunol. 174 (2005) 4908-4915
22. Prabakaran P., Gan J., Feng Y., Zhu Z., Choudhry V., Xiao X., et al. Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody. J. Biol. Chem. 281 (2006) 15829-15836
23. Sui J., Li W., Murakami A., Tamin A., Matthews L.J., Wong S.K., et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc. Natl Acad. Sci. USA 101 (2004) 2536-2541
24. van den Brink E.N., Ter Meulen J., Cox F., Jongeneelen M.A., Thijsse A., Throsby M., et al. Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus. J. Virol. 79 (2005) 1635-1644
25. Hwang W.C., Lin Y., Santelli E., Sui J., Jaroszewski L., Stec B., et al. Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R. J. Biol. Chem. 281 (2006) 34610-34616
26. Gubbins M.J., Plummer F.A., Yuan X.Y., Johnstone D., Drebot M., Andonova M., et al. Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus. Mol. Immunol. 42 (2005) 125-136
27. Stanfield R.L., Zemla A., Wilson I.A., and Rupp B. Antibody elbow angles are influenced by their light chain class. J. Mol. Biol. 357 (2006) 1566-1574
28. Al-Lazikani B., Lesk A.M., and Chothia C. Standard conformations for the canonical structures of immunoglobulins. J. Mol. Biol. 273 (1997) 927-948
29. Lawrence M.C., and Colman P.M. Shape complementarity at protein/protein interfaces. J. Mol. Biol. 234 (1993) 946-950
30. Wilson I.A., and Stanfield R.L. Antibody-antigen interactions: new structures and new conformational changes. Curr. Opin. Struct. Biol. 4 (1994) 857-867
31. Zhu Z., Chakraborti S., He Y., Roberts A., Sheahan T., Xiao X., et al. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc. Natl Acad. Sci. USA 104 (2007) 12123-12128
32. Burton D.R., Williamson R.A., and Parren P.W. Antibody and virus: binding and neutralization. Virology 270 (2000) 1-3
33. Klasse P.J., and Sattentau Q.J. Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J. Gen. Virol. 83 (2002) 2091-2108
34. Parren P.W., and Burton D.R. The antiviral activity of antibodies in vitro and in vivo. Adv. Immunol. 77 (2001) 195-262
35. Reading S.A., and Dimmock N.J. Neutralization of animal virus infectivity by antibody. Arch. Virol. 152 (2007) 1047-1059
36. Knossow M., Gaudier M., Douglas A., Barrere B., Bizebard T., Barbey C., et al. Mechanism of neutralization of influenza virus infectivity by antibodies. Virology 302 (2002) 294-298
37. Knossow M., and Skehel J.J. Variation and infectivity neutralization in influenza. Immunology 119 (2006) 1-7
38. He Y., Li J., Li W., Lustigman S., Farzan M., and Jiang S. Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. J. Immunol. 176 (2006) 6085-6092
39. Beniac D.R., Andonov A., Grudeski E., and Booth T.F. Architecture of the SARS coronavirus prefusion spike. Nat. Struct. Mol. Biol. 13 (2006) 751-752
40. Beniac D.R., Devarennes S.L., Andonov A., He R., and Booth T.F. Conformational reorganization of the SARS coronavirus spike following receptor binding: implications for membrane fusion. PLoS ONE 2 (2007) e1082
41. Yang Z.Y., Werner H.C., Kong W.P., Leung K., Traggiai E., Lanzavecchia A., and Nabel G.J. Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc. Natl Acad. Sci. USA 102 (2005) 797-801
42. Pantophlet R., and Burton D.R. GP120: target for neutralizing HIV-1 antibodies. Annu. Rev. Immunol. 24 (2006) 739-769
43. Wei C.J., Xu L., Kong W.P., Shi W., Canis K., Stevens J., et al. Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus. J. Virol. 82 (2008) 6200-6208
44. Koch M., Pancera M., Kwong P.D., Kolchinsky P., Grundner C., Wang L., et al. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology 313 (2003) 387-400
45. Li W., Zhang C., Sui J., Kuhn J.H., Moore M.J., Luo S., et al. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J. 24 (2005) 1634-1643
46. Pak J.E., and Rini J.M. X-ray crystal structure determination of mammalian glycosyltransferases. Methods Enzymol. 416 (2006) 30-48
47. Otwinowski Z., and Minor W. Processing of X-ray diffraction data collected in oscillation mode. In: Carter Jr. C.W. (Ed). Methods in Enzymology 276 (1997), Academic Press, Orlando, FL 307-326
48. McCoy A.J., Grosse-Kunstleve R.W., Storoni L.C., and Read R.J. Likelihood-enhanced fast translation functions. Acta Crystallogr., Sect. D: Biol. Crystallogr. 61 (2005) 458-464
49. Brunger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., et al. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr., Sect D: Biol. Crystallogr. 54 (1998) 905-921
50. Murshudov G.N., Vagin A.A., and Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr., Sect. D: Biol. Crystallogr. 53 (1997) 240-255
51. Emsley P., and Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr., Sect. D: Biol. Crystallogr. 60 (2004) 2126-2132